The purpose of this study is to observe the safety of Truvada® (TDF/FTC) in relation to its
impact on kidney function combined with different Integrase Inhibitors (Dolutegravir, or
Elvitegravir/Cobicistat or Raltegravir), when given to patients who are commencing treatment
for HIV infection for the first time.
All three combinations (Raltegravir + Truvada®, Dolutegravir + Truvada® and Stribild®, a
single pill which contains Elvitegravir/Cobicistat/Truvada®) are currently recommended by the
national guide-lines and used in standard clinical practice.
Phase:
Phase 4
Details
Lead Sponsor:
St Stephens Aids Trust
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Cobicistat Dolutegravir Elvitegravir Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium Tenofovir